PART I Overview Since its founding in 2009, Kodiak Sciences Inc. (Kodiak, the Company, we or our) has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Our goal is to prevent and treat the major causes of blindness by developing and commercializing next-generation therapeutics to address multiple unmet needs on the spectrum of retinal diseases. Kodiak has developed three late-stage clinical programs based on its internal discovery and d...
Q2 FY2026 — expected 2026-08-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001193125-26-134887 | EDGAR | 81K words |
| 2025-03-27 | 2024-12-31 | 0000950170-25-046098 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0000950170-24-038025 | EDGAR | — |
| 2023-03-28 | 2022-12-31 | 0000950170-23-010314 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0000950170-22-002555 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001564590-21-009946 | EDGAR | — |
| 2020-03-16 | 2019-12-31 | 0001564590-20-011186 | EDGAR | — |
| 2019-03-27 | 2018-12-31 | 0001564590-19-009601 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001193125-25-280183 | EDGAR | 54K words |
| 2025-08-13 | 2025-06-30 | 0000950170-25-108033 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0000950170-25-071523 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0000950170-24-127059 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0000950170-24-097010 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0000950170-24-060483 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0000950170-23-063767 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0000950170-23-042479 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0000950170-23-022203 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023870 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-016151 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0000950170-22-008956 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-31 | 0001193125-26-134854 | EDGAR | 4K words |
| 2026-03-27 | 0001193125-26-127041 | EDGAR | — |
| 2025-12-18 | 0001193125-25-324882 | EDGAR | — |
| 2025-11-13 | 0001193125-25-280125 | EDGAR | — |
| 2025-08-13 | 0000950170-25-107982 | EDGAR | — |
| 2025-06-03 | 0001193125-25-134149 | EDGAR | — |
| 2025-05-14 | 0000950170-25-071474 | EDGAR | — |
| 2025-03-27 | 0000950170-25-046067 | EDGAR | — |
| 2024-11-14 | 0000950170-24-127029 | EDGAR | — |
| 2024-08-14 | 0000950170-24-096985 | EDGAR | — |
110 total filings indexed. 80 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001468748 |
| Ticker | KOD |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.kodiak.com |
| Listed | 2018-10-04 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report